Monday, November 05, 2018 8:12:15 PM
So as not to compare apples to oranges, take a look at the competition. E.g. DVAX TLR9 with some 70% BORR for PD-L1 naive vs. 21,4% BORR in resistant/refractory melanoma*. So I expect some 25-35% responders for Tavo. Probably this is one of the lowest estimates in this forum. Why?
Because if I understand correctly, the trial allows ipi non-responders or patients with failed prior immunotherapies to enroll (I do not see such an exclusion https://clinicaltrials.gov/ct2/show/NCT03132675, on the contrary*). So these are patients that have no other approved therapy left. This has to be, since that is the only trial population for which the FDA would allow an accelerated approval (i.e. based on single-arm ph II Pisces because of the "unmet need" ... avoiding a costly and lengthy ph III study).
Sigh, let's see. Probably I should not look at my shares tomorrow.
dM
*
http://investors.dynavax.com/static-files/7caf0c83-2cd2-44db-8074-e50593716dc2
http://investors.dynavax.com/static-files/4495d7ad-f36a-4047-a8b1-5405a8772603
**
among the exclusion criteria: "Subject has disease that is suitable for local therapy administered with curative intent." - I wonder whether this alludes to imiquimod and/or T-Vec
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM